Serlopitant Not Statistically Significantly Better Than Placebo in Prurigo Nodularis Studies
Menlo Therapeutics announced topline results from two phase 3 studies of serlopitant for the treatment of pruritus associated with prurigo nodularis.
Menlo Therapeutics announced topline results from two phase 3 studies of serlopitant for the treatment of pruritus associated with prurigo nodularis.
Vanda Pharmaceuticals announced data from the phase 3 EPIONE study of tradipitant for the treatment of pruritus in atopic dermatitis. The 8-week, multicenter, double-blind, placebo-controlled study evaluated the efficacy of tradipitant, a neurokinin-1 receptor antagonist, in 341 adult patients with atopic dermatitis who presented with severe pruritus. Patients were randomized 1:1 to receive either tradipitant…
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to nemolizumab (Galderma) for the treatment of pruritus associated with prurigo nodularis. Prurigo nodularis is a rare skin disease that is characterized by the formation of hard, itchy nodules on the skin. It is commonly associated with intense itching that may lead to severe…
The KALM-1 trial was a multicenter, double-blind, placebo-controlled 12-week study with a 52-week open label extension phase that evaluated the safety and efficacy of Korsuva injection in 350 hemodialysis patients
Lilly and Incyte announced positive top-line results from two Phase 3 clinical trials evaluating baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis. Results from the BREEZE-AD1 and BREEZE-AD2 placebo-controlled trials showed that treatment with baricitinib monotherapy led to a statistically significant proportion of patients achieving Investigator’s Global Assessment for Atopic Dermatitis score of clear…
Management is generally in a stepwise manner, including moisturizers and avoiding triggers
The mean cumulative lifetime prevalence of atopic eczema is 9.9%, according to a research letter.
Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.
The Phase 3 trial enrolled 251 patients aged 12-17 years old with moderate-to-severe atopic dermatitis, whose disease was not adequately controlled by prescription topical medications or for whom topical treatment was medically inadvisable.
Many patients with moderate/severe atopic dermatitis have inadequate disease control